awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3
Q33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3
New knowledge of the mechanisms of sorafenib resistance in liver cancer
P2860
Q33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
075b4316fd13d563a6e4e895654394ac7c191a92
P2860
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.